In this edition, obesity linked to adverse outcomes among AYAs; pirtobrutinib produces high response rates; CDC study reveals overall increase in pediatric cancer incidence and more.
Read the full coverage here:
Overweight, obesity linked to adverse outcomes among AYAs treated for leukemia
Pirtobrutinib produces high response rates in heavily pretreated CLL, SLL
CDC study reveals overall increase in pediatric cancer incidence over 16 years
Cancers with high incidence among racial/ethnic minorities receive less research funding
Women more likely to experience severe toxicity from cancer treatment
References:
Haghighat S, et al. J Natl Cancer Inst. 2023;doi:10.1093/jnci/djad097.
Mato AR, et al. N Engl J Med. 2023;doi:10.1056/NEJMoa2300696.
Shimony S, et al. Blood Adv. 2023;doi:10.1182/bloodadvances.2023009976.
Siegel DA, et al. J Natl Cancer Inst. 2023;doi:10.1093/jnci/djad115.
Unger JM, et al. Abstract SY43-03. Presented at American Association for Cancer Research Annual Meeting; April 14-19, 2023; Orlando.
